These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 14972081

  • 21. [Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses].
    Chabannes JP, Pelissolo A, Farah S, Gerard D.
    Encephale; 1998; 24(4):386-92. PubMed ID: 9809244
    [Abstract] [Full Text] [Related]

  • 22. Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine.
    Hofer A, Rettenbacher MA, Edlinger M, Huber R, Bodner T, Kemmler G, Sachs G, Fleischhacker WW.
    Pharmacopsychiatry; 2007 Jan; 40(1):1-8. PubMed ID: 17327953
    [Abstract] [Full Text] [Related]

  • 23. Current use of atypical antipsychotics.
    Müller-Spahn F.
    Eur Psychiatry; 2002 Aug; 17 Suppl 4():377s-384s. PubMed ID: 23573608
    [Abstract] [Full Text] [Related]

  • 24. Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride.
    Linden M, Eich FX, Pyrkosch L.
    Int Clin Psychopharmacol; 2007 May; 22(3):175-8. PubMed ID: 17414744
    [Abstract] [Full Text] [Related]

  • 25. Amisulpride: progress and outcomes.
    Lecrubier Y.
    Curr Med Res Opin; 2002 May; 18 Suppl 3():s18-22. PubMed ID: 12418608
    [Abstract] [Full Text] [Related]

  • 26. The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia.
    Kim SW, Shin IS, Kim JM, Youn T, Yang SJ, Hwang MY, Yoon JS.
    Clin Neuropharmacol; 2009 May; 32(4):224-6. PubMed ID: 19644229
    [Abstract] [Full Text] [Related]

  • 27. [Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature].
    Pélissolo A, Krebs MO, Olié JP.
    Encephale; 1996 May; 22(3):215-9. PubMed ID: 8767050
    [Abstract] [Full Text] [Related]

  • 28. Atypical antipsychotics: mechanism of action.
    Seeman P.
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [Abstract] [Full Text] [Related]

  • 29. Focus on amisulpride.
    Green B.
    Curr Med Res Opin; 2002 Feb; 18(3):113-7. PubMed ID: 12094819
    [Abstract] [Full Text] [Related]

  • 30. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia.
    Mortimer A, Martin S, Lôo H, Peuskens J, SOLIANOL Sudy Group.
    Int Clin Psychopharmacol; 2004 Mar; 19(2):63-9. PubMed ID: 15076013
    [Abstract] [Full Text] [Related]

  • 31. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride.
    Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, Kühn KU.
    Neuropsychopharmacology; 2005 Feb; 30(2):381-90. PubMed ID: 15578006
    [Abstract] [Full Text] [Related]

  • 32. Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia.
    Kasper S.
    Int Clin Psychopharmacol; 2002 Dec; 17 Suppl 4():S19-26. PubMed ID: 12685918
    [Abstract] [Full Text] [Related]

  • 33. Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia.
    Lecrubier Y, Azorin M, Bottai T, Dalery J, Garreau G, Lempérière T, Lisoprawski A, Petitjean F, Vanelle JM.
    Neuropsychobiology; 2001 Dec; 44(1):41-6. PubMed ID: 11408792
    [Abstract] [Full Text] [Related]

  • 34. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression.
    Vanelle JM, Douki S.
    Eur Psychiatry; 2006 Dec; 21(8):523-30. PubMed ID: 17113759
    [Abstract] [Full Text] [Related]

  • 35. Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride.
    Saleem P, Olié JP, Loo H.
    Int Clin Psychopharmacol; 2002 Jan; 17(1):1-8. PubMed ID: 11806403
    [Abstract] [Full Text] [Related]

  • 36. Amisulpride for the treatment of very-late-onset schizophrenia-like psychosis.
    Psarros C, Theleritis CG, Paparrigopoulos TJ, Politis AM, Papadimitriou GN.
    Int J Geriatr Psychiatry; 2009 May; 24(5):518-22. PubMed ID: 19072747
    [Abstract] [Full Text] [Related]

  • 37. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.
    Müller MJ, Regenbogen B, Sachse J, Eich FX, Härtter S, Hiemke C.
    Pharmacopsychiatry; 2006 Mar; 39(2):41-6. PubMed ID: 16555163
    [Abstract] [Full Text] [Related]

  • 38. Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine.
    Molina JD, Toledo-Romero F, López-Rodríguez E, Amorin-Díaz M, Lerma-Carrillo I, López-Muñoz F.
    Pharmacopsychiatry; 2011 Jun; 44(4):142-7. PubMed ID: 21710404
    [Abstract] [Full Text] [Related]

  • 39. DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment.
    Kang SG, Na KS, Lee HJ, Chee IS, Lee K, Lee J.
    J Clin Psychopharmacol; 2015 Apr; 35(2):158-62. PubMed ID: 25679126
    [Abstract] [Full Text] [Related]

  • 40. Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine.
    Quednow BB, Wagner M, Westheide J, Beckmann K, Bliesener N, Maier W, Kühn KU.
    Biol Psychiatry; 2006 Mar 15; 59(6):536-45. PubMed ID: 16139819
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.